Biotronik launches CardioMessenger smart device in USA


Biotronik has launched CardioMessenger Smart in the USA. CardioMessenger Smart is a portable monitoring device, about the size of a smartphone, which makes data from pacemaker, implantable cardioverter defibrillator (ICD), and insertable cardiac monitor (ICM) patients available remotely to their physician.

CardioMessenger Smart is designed to provide secure, automatic transmission of information from a patient’s cardiac implant to their physician via Biotronik Home Monitoring. This includes daily, automatic reports and fully customisable alerts that can be programmed to the physician’s specifications. As demonstrated by the TRUST1, COMPAS2 and IN-TIME3 clinical studies, home monitoring can significantly reduce hospitalisation, stroke and mortality. CardioMessenger Smart recently received US Food and Drug Administration approval.

“The clinical and economic benefits of remote monitoring have been well established over a decade of clinical studies,” states Niraj Varma, in reference to the 2015 Heart Rhythm Society (HRS) Expert Consensus Statement on remote monitoring. “But these benefits are only realised if patients consistently use the technology. When we make the remote monitoring process easy for patients, we increase the likelihood of patient adherence, which has been demonstrated to improve health outcomes.” Varma was lead investigator for the TRUST trial, which laid the foundation for the guidelines, and co-chair of the HRS committee.

The portability of CardioMessenger Smart is intended to ensure patient compliance and the consistent transmission of data necessary for physicians to identify and prevent potential cardiac events. CardioMessenger Smart is fully automatic, providing daily reports of cardiac activity via worldwide cellular networks to physicians without intervention from the patient.